📅 Published: April 15, 2026 | Morning Edition
Pricing Power: The Most Underrated Moat in Value Investing — How to Identify Indian Companies That Can Raise Prices Year After Year Without Losing Customers
There is one question every serious value investor must ask before buying any business: Can this company raise its prices next year — and the year after — without watching its customers walk away?
The answer to that single question separates the generational wealth-creators from the pretenders. It separates Asian Paints from a generic paint company. It separates Pidilite Industries from a commodity adhesive maker. It separates Nestle India’s Maggi from the dozens of noodle brands that tried and failed to dislodge it. And, increasingly, it separates Titan Biotech Ltd (BSE: 524717) — trading at ₹430 today with a market cap of ₹1,779 crores — from the hundreds of small-cap pharma companies competing purely on price.
This article is your complete guide to understanding, measuring, and profiting from Pricing Power — the single most underrated competitive moat in the Indian stock market.
What Is Pricing Power — And Why Does It Matter So Much?
Pricing power is a company’s ability to raise the prices of its products or services over time — consistently, sustainably, and without causing customers to defect to competitors or substitutes.
It sounds simple. But the economic implications are profound.
India’s inflation rate has averaged approximately 5-6% annually over the past decade. Every year, raw material costs rise. Labour costs rise. Energy costs rise. A company without pricing power has only one option: absorb those costs and watch its profit margins quietly shrink. A company WITH pricing power simply passes those costs along to customers — often with a small premium on top — and protects or even expands its margins.
Warren Buffett famously said: “The single most important decision in evaluating a business is pricing power. If you’ve got the power to raise prices without losing business to a competitor, you’ve got a very good business. And if you have to have a prayer session before raising the price by a tenth of a cent, then you’ve got a terrible business.”
In the Indian context, pricing power is even more critical. With cost inflation structural (not cyclical), companies that cannot defend their margins become value destroyers over time — even if their revenue grows. A ₹100 crore revenue company growing at 15% annually but seeing margins compress from 20% to 12% is actually getting poorer, not richer, on a per-share basis.
The 5 Sources of Pricing Power — Know Where It Comes From
Pricing power doesn’t just appear. It is built — over years and decades — through one or more of these five structural advantages:
1. Brand Dominance
When a customer asks for your brand by name — not just your product category — you have pricing power. Nestle India charges a significant premium for Maggi noodles over generic competitors because millions of Indian households have an emotional connection to the brand built over 40+ years. Asian Paints commands premium pricing in decorative paints not because its paint is chemically unique, but because contractors, homeowners, and architects trust the brand implicitly. Brand dominance converts a commodity into a premium product — and that is pure pricing power.
2. Switching Costs
If changing from your product to a competitor’s product is painful, expensive, or risky, customers will tolerate price increases rather than switch. This is particularly powerful in B2B (business-to-business) markets. A pharmaceutical company that has been supplying Titan Biotech’s biological raw materials and microbial culture media for years faces enormous switching costs — revalidation, regulatory re-approval, clinical stability studies. Those switching costs give Titan Biotech the ability to raise prices gradually without fear of losing institutional customers overnight.
3. Market Dominance / Quasi-Monopoly
Pidilite Industries controls approximately 70% of the Indian adhesives market through Fevicol. When Pidilite raises prices — which it does regularly — carpenters across India have nowhere else to go. The alternatives are technically inferior, less trusted, and simply less available. This quasi-monopoly position is a textbook source of pricing power. In specialty chemicals, specialty biologics, and niche industrial products, Indian companies with dominant market share enjoy the same advantage.
4. Essential Products With No Substitutes
When your product is essential and there is no viable substitute, customers simply pay the higher price. This is why pharmaceutical companies — both branded drug makers and raw material suppliers — often have extraordinary pricing power for specific molecules. A hospital cannot tell a critically ill patient to wait for a cheaper supplier. Titan Biotech, as a manufacturer of specialty biological products including diagnostic reagents, culture media, and biochemicals used in pharmaceutical manufacturing, benefits directly from this principle: no pharma company will risk product quality by switching to an untested cheaper supplier for a ₹50,000 input that goes into a ₹5 crore drug product.
5. Premium Positioning & Aspirational Value
In consumer markets, premium positioning creates its own pricing power. Page Industries (Jockey’s licensee), Titan Company’s watches, and Bata India’s premium lines — these brands sell not just products but aspirations. Their customers are willing to pay a premium because the product signals something about who they are. Raising prices for aspirational brands can actually increase demand (the Veblen Effect) by reinforcing the brand’s premium status.
How to MEASURE Pricing Power — The Forensic Tests
Theory is fine. But as a value investor, you need concrete, measurable signals that a company actually has pricing power. Here is your forensic checklist:
Test 1: Gross Margin Stability Over 10 Years
Pull up 10 years of gross margin data from Screener.in or the annual reports. A company with true pricing power will show stable or expanding gross margins over a full decade — including periods of commodity inflation. If gross margins compressed significantly during 2021-22 (when commodity costs spiked globally) and never recovered, the company lacks pricing power. If margins held steady or expanded, you have found something special.
Test 2: Operating Margin Trend
Titan Biotech’s operating margin has expanded from approximately 10% in FY2015 to approximately 19% in FY2025. That is not luck — it is the compounding of pricing power over time. When a company can raise prices faster than costs rise, operating margins naturally expand. Look for companies where OPM has risen by at least 3-5 percentage points over a decade — these are almost always companies with genuine pricing power.
Test 3: Revenue Per Unit Growth (Realisation)
Divide revenue by volume (units sold, tonnes, litres, etc.) to calculate the revenue per unit. If revenue per unit has grown faster than inflation over a 5-10 year period, the company has been successfully raising prices. This data is often available in the Management Discussion & Analysis (MD&A) section of annual reports under “realisation per tonne” or similar metrics for commodity-adjacent businesses.
Test 4: Competitor Response to Price Increases
Read the earnings concalls and annual reports of competitors. Do they follow the market leader’s price increases? If the market leader raises prices and everyone else follows within 1-2 quarters, you have found a company with true pricing leadership. If competitors REFUSE to follow the price increase and gain market share as a result, the first company lacks genuine pricing power and may be sacrificing volume for short-term margin.
Test 5: Customer Retention and Repeat Business
In B2B businesses like Titan Biotech’s, a critical signal is whether long-standing customer relationships survive price increases. When management mentions in concalls that “our key customers have been with us for 8-15 years” and revenue from repeat customers remains above 85%, it is direct evidence that pricing adjustments are being absorbed — not rejected — by the customer base.
Real Indian Examples: Where Pricing Power Created Multibaggers
Let’s look at the Indian stock market’s most powerful illustrations of pricing power in action:
Asian Paints has compounded its stock price by approximately 500x since its IPO. The secret? Decorative paints in India are not a commodity in the consumer’s mind — they’re a brand. Asian Paints has raised prices 18+ times in the past decade. Each time, consumers grumbled briefly, then paid. The company’s gross margins have remained in the 42-47% range even as crude oil (a key raw material input) swings wildly.
Pidilite Industries sells Fevicol at approximately 4-5x the price of generic adhesives. The product is technically similar. But the brand is so dominant — “Fevicol ka jod” is a phrase in the Indian cultural lexicon — that price sensitivity has effectively been neutralised. The result: ROCE of 40%+, gross margins of 50%+, and a stock that has created extraordinary wealth over decades.
Nestle India raised Maggi noodle prices during the post-2015 comeback (after the contamination scare) and still grew volume. That is the ultimate proof of pricing power: surviving a complete market exit, re-entering, raising prices above previous levels, and capturing MORE market share.
Titan Biotech operates in a space — specialty biological products, diagnostic media, pharma raw materials — where quality, consistency, and regulatory compliance matter infinitely more than price. With exports across 100+ countries, a cGMP-certified facility, ISO 9001 certification, and a product portfolio of 100+ items across 7 categories, the company has built exactly the kind of structural moat that enables measured, consistent price increases. Its 15% revenue CAGR over a decade, paired with margin expansion from 10% to 19% OPM, is the fingerprint of pricing power at work.
Where Pricing Power Does NOT Exist — The Warning Signs
As critical as knowing WHERE to find pricing power is knowing WHERE IT IS ABSENT. Avoid companies with these characteristics:
Commodity businesses: Steel, cement (to a large extent), basic chemicals, cotton yarn — these industries compete almost entirely on price. Margins compress during industry downturns regardless of management quality. While they can be excellent cyclical trades, they are not long-term wealth compounders.
Undifferentiated generic products: Generic pharmaceutical API manufacturers who compete on cost with Chinese producers have no pricing power. As soon as China floods the market with a particular molecule, Indian API makers face brutal margin compression.
Contract manufacturing with price pressure: Companies that manufacture for large FMCG or industrial clients on a cost-plus basis have their pricing entirely dictated by the customer. They are the opposite of pricing power businesses.
High customer concentration with powerful buyers: If a company derives 50%+ of revenue from 2-3 large customers who have significant negotiating power (like large e-commerce platforms or government PSUs), pricing power is effectively absent.
The Compounding Effect: Why Pricing Power Compounds Wealth
Here is the mathematical magic that most investors miss: pricing power compounds nonlinearly.
Assume a company with ₹100 crore revenue and 20% operating margins (₹20 crore EBIT) raises prices by just 5% annually while volume stays flat and costs rise by 3% annually. After 10 years:
Revenue grows to ₹163 crore (5% CAGR). Costs grow to ₹130 crore (3% CAGR on ₹80 crore cost base). EBIT grows to ₹33 crore — a 65% increase in absolute profit with ZERO volume growth. Operating margins expand from 20% to over 20%+. Stock prices, which ultimately follow earnings, rise accordingly.
Now compound that over 20 years, and you understand why Asian Paints and Pidilite have created generational wealth. The engine is not spectacular revenue growth. It is the steady, compounding discipline of raising prices 4-6% per year while keeping volume stable and costs controlled.
How to Build a “Pricing Power Portfolio” — The Practical Approach
For Indian value investors seeking to build positions in pricing power businesses, the framework is straightforward:
Step 1 — Screen for gross margin stability. On Screener.in, filter for companies where gross margins have been above 30% consistently for 10 years. This immediately eliminates most commodity and low-quality businesses.
Step 2 — Check operating margin trajectory. Among those that pass Step 1, identify companies where OPM has been expanding — not just stable — over the decade. Expansion is the fingerprint of pricing power working in real time.
Step 3 — Read the annual report for qualitative signals. Look for phrases like “passing on cost increases to customers,” “volume growth despite price increase,” “premium pricing reflecting quality differentiation,” and “long-term customer relationships.” These are management admissions of pricing power.
Step 4 — Check revenue per unit / realisation trends. Confirm that the company is actually charging more per unit over time — not just growing revenue through volume.
Step 5 — Stress test with competitor analysis. Look at whether the competitors in the same space are suffering margin compression while your target company is holding or expanding margins. That divergence is the ultimate confirmation of a superior competitive position.
Titan Biotech: A Pricing Power Case Study in the Making
As of April 15, 2026, Titan Biotech trades at ₹430 per share with a ROCE of 17.7%, ROE of 13.4%, near-zero debt (D/E of 0.02x), and promoter holding of 55.78%. The company recently completed a 1:5 stock split, making shares more accessible to retail investors.
More importantly, the company’s 10-year financial journey shows precisely what pricing power looks like in a specialty biologics business: consistent revenue growth of 15% CAGR, operating margin expansion from 10% to 19%, cash flow quality that matches reported earnings, and export revenue from 100+ countries that validates international pricing acceptance.
A pharmaceutical company in Germany or the USA that uses Titan Biotech’s culture media for clinical manufacturing is NOT switching suppliers to save ₹2,000 on a ₹50,000 order. The regulatory re-validation cost and time would be 100x the savings. That is structural pricing power — built not through marketing, but through quality, compliance, and trust accumulated over decades.
Key Takeaways for the Smart Indian Value Investor
1. Pricing power is the highest form of competitive moat — it compounds wealth silently but powerfully over decades.
2. Measure it through gross margin stability, OPM expansion, and revenue per unit growth — not through management claims alone.
3. The five sources of pricing power are: brand dominance, switching costs, quasi-monopoly market position, essential products with no substitutes, and premium aspirational positioning.
4. Avoid commodity businesses, undifferentiated generics, and contract manufacturers — they have structural pricing weakness baked in.
5. Companies with pricing power don’t need spectacular volume growth — steady price increases + stable volume = powerful earnings compounding over time.
The greatest investors in history — Buffett, Munger, Fisher — all emphasised pricing power as a primary criterion. In the Indian market, it is still underappreciated by the majority. That underappreciation is your opportunity.
📣 Join our Telegram channel for daily value investing insights: https://t.me/longtermequityy
⚠️ DISCLAIMER: Manish Goel is a SEBI Registered Research Analyst (INH100004775) and Multibagger Shares is a SEBI Registered Investment Advisor (INA100007736). This article is for educational purposes only and does not constitute investment advice. Investments in the securities market are subject to market risks. Please read all related documents carefully before investing. Past performance is not indicative of future results. The examples of stocks mentioned (Titan Biotech, Asian Paints, Pidilite, Nestle India, etc.) are for educational illustration only and do not constitute a recommendation to buy or sell any security. Please consult your financial advisor before making any investment decisions.
